Forma Therapeutics Holdings

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The mean of analysts' price targets for Forma Therapeutics Holdings, Inc. (FMTX) points to a 379.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Forma Therapeutics Holdings, Inc. (FMTX)? Wall Street Analysts Think 379%

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Announces Appointment of New Executive Team Members

Forma Therapeutics Announces Appointment of New Executive Team Members

The average of price targets set by Wall Street analysts indicates a potential upside of 536% in Forma Therapeutics Holdings, Inc. (FMTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Forma Therapeutics Holdings, Inc. (FMTX) Climb 536% to Reach the Level Wall Street Analysts Expect?

Forma Therapeutics Holdings, Inc. (FMTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over Forma Therapeutics Holdings, Inc. (FMTX), Here's Why It's a 'Buy' Now

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Announces Presentations at Upcoming Hematology Conferences

Forma Therapeutics Announces Presentations at Upcoming Hematology Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Present at the Jefferies Healthcare Conference

Forma Therapeutics to Present at the Jefferies Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development Day

Forma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) Day

Forma Therapeutics Holdings Inc. (NASDAQ:FMTX ) Q1 2022 Earnings Conference Call May 6, 2022 8:00 AM ET Company Participants Frank Lee – President and Chief Executive Officer Mario Corso – Senior Director Investor Relations Patrick Kelly – Chief Medical Officer Dave Cook – Chief Scientific Officer Conference Call Participants Maury Raycroft – Jefferies Mark Breidenbach – Oppenheimer Robin Garner – Craig Hallum Operator Welcome to the Forma Therapeutics, First Quarter 2022 Financial Results and Business Update Conference Call. All participants are currently in listen-only mode.

Forma Therapeutics Holdings Inc. (FMTX) CEO Frank Lee on Q1 2022 Results - Earnings Call Transcript

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Forma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022

Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022

Forma Therapeutics Holdings' (FMTX) CEO Frank Lee on Q4 2021 Results - Earnings Call Transcript

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

Forma Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022

Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference

Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee

Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

Agios Pharmaceuticals

bluebird bio

Bristol-Myers

Big pharma companies and small biotechs alike emerged from the key American Society of Hematology conference as big winners.

4 Biotechs That Were Winners at ASH

The mean of analysts' price targets for Forma Therapeutics Holdings, Inc. (FMTX) points to a 277.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can Forma Therapeutics Holdings, Inc. (FMTX) Climb 277% to Reach the Level Wall Street Analysts Expect?

Forma Therapeutics (FMTX) has been struggling lately, but the selling pressure may be coming to an end soon.

Forma Therapeutics (FMTX) Sees Hammer Chart Pattern: Time to Buy?

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma's Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia

Forma Therapeutics' Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia

Forma's (FMTX) investigational PKR activator, etavopivat significantly improves anemia and red blood cell health in patients with sickle cell disease.

Forma's (FMTX) Etavopivat Proves Safety Profile in SCD Study

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics' Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease

Forma Therapeutics' Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell Disease

Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell Disease

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Appoints Acclaimed Global Sickle Cell Disease Leader, Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer

Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer

The average of price targets set by Wall Street analysts indicates a potential upside of 184.6% in Forma Therapeutics Holdings, Inc. (FMTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

News for Forma Therapeutics Holdings Stock (FMTX)